| 250.7648 8.165 (3.37%) | 07-07 14:53 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 303.9 | 1-year : | 354.95 |
| Resists | First : | 260.19 | Second : | 303.9 |
| Pivot price | 245.29  |
|||
| Supports | First : | 233.59 | Second : | 217.15 |
| MAs | MA(5) : | 244.73 |
MA(20) : | 245.77 |
| MA(100) : | 200.88 |
MA(250) : | 162.3 |
|
| MACD | MACD : | 3.9 |
Signal : | 4.9 |
| %K %D | K(14,3) : | 40.5 |
D(3) : | 31.6 |
| RSI | RSI(14): 62.3 |
|||
| 52-week | High : | 260.19 | Low : | 96.08 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AXSM ] has closed below upper band by 21.4%. Bollinger Bands are 25.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 251.84 - 253.08 | 253.08 - 254.08 |
| Low: | 235.67 - 237.32 | 237.32 - 238.65 |
| Close: | 240.29 - 242.79 | 242.79 - 244.81 |
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Tue, 07 Jul 2026
Axsome starts Phase 3 ADHD trial in children, enrolling 468 patients - Stock Titan
Sun, 05 Jul 2026
Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock - Stocktwits
Sun, 05 Jul 2026
The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Phase 3 ADHD Trial And Index Moves - simplywall.st
Sun, 05 Jul 2026
HB Wealth Management LLC Grows Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 51 (M) |
| Shares Float | 44 (M) |
| Held by Insiders | 15.3 (%) |
| Held by Institutions | 76.5 (%) |
| Shares Short | 3,280 (K) |
| Shares Short P.Month | 2,780 (K) |
| EPS | -3.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.05 |
| Profit Margin | -26.6 % |
| Operating Margin | -32.9 % |
| Return on Assets (ttm) | -16.9 % |
| Return on Equity (ttm) | -349.4 % |
| Qtrly Rev. Growth | 57.4 % |
| Gross Profit (p.s.) | 12.74 |
| Sales Per Share | 13.76 |
| EBITDA (p.s.) | -3.25 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -71 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -67.57 |
| PEG Ratio | 0 |
| Price to Book value | 237.09 |
| Price to Sales | 18.26 |
| Price to Cash Flow | -182.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|